These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23711732)

  • 1. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.
    Knops N; Levtchenko E; van den Heuvel B; Kuypers D
    Int J Pharm; 2013 Aug; 452(1-2):14-35. PubMed ID: 23711732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
    de Jonge H; Naesens M; Kuypers DR
    Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.
    Vanhove T; Annaert P; Kuypers DR
    Drug Metab Rev; 2016; 48(1):88-112. PubMed ID: 26912097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.
    Press RR; de Fijter JW; Guchelaar HJ
    Curr Pharm Des; 2010; 16(2):176-86. PubMed ID: 20205663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
    Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
    Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report.
    Malireddy SR; Pinto AG; Chalasani NP; Gorski JC; Hall SD
    Transplant Proc; 2008 Jun; 40(5):1789-91. PubMed ID: 18589198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.
    Fu R; Tajima S; Suetsugu K; Watanabe H; Egashira N; Masuda S
    Acta Pharmacol Sin; 2019 Feb; 40(2):151-159. PubMed ID: 29950613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of genetic polymorphism on disposition of calcineurin inhibitors in solid organ transplantation].
    Li D; Zhu L; Ye Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 35(9):1018-22. PubMed ID: 20871172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
    Thervet E; Legendre C; Beaune P; Anglicheau D
    Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
    Blanchet B
    Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of calcineurin antagonists.
    Kapturczak MH; Meier-Kriesche HU; Kaplan B
    Transplant Proc; 2004 Mar; 36(2 Suppl):25S-32S. PubMed ID: 15041303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation.
    van Gelder T; Fischer L; Shihab F; Shipkova M
    Transplant Rev (Orlando); 2017 Jul; 31(3):151-157. PubMed ID: 28279567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients.
    Plank C; Benz K; Amann K; Nüsken KD; Dittrich K; Rascher W; Sauerstein K; Stuppy A; Klare B; Dötsch J
    Nephrol Dial Transplant; 2006 Oct; 21(10):2930-7. PubMed ID: 16837512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic concentrations of calcineurin inhibitors do not deregulate glutathione redox balance in human renal proximal tubule cells.
    Ramazani Y; Knops N; Berlingerio SP; Adebayo OC; Lismont C; Kuypers DJ; Levtchenko E; van den Heuvel LP; Fransen M
    PLoS One; 2021; 16(4):e0250996. PubMed ID: 33930094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
    Issa N; Kukla A; Ibrahim HN
    Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.